Peregrine Pharmaceuticals Reports Fourth Quarter and Year-End Fiscal Year 2015 Financial Results and Recent Developments
July 14, 2015 16:05 ET
|
Peregrine Pharmaceuticals Inc.
-- Phase III SUNRISE Clinical Trial on Track to Complete Patient Enrollment by Calendar Year-End 2015 – -- Initiation of Later-Stage Bavituximab Trials to Expand Commercial Potential in NSCLC and...
Peregrine to Report Fourth Quarter and Year-End Fiscal Year 2015 Financial Results After Market Close on July 14, 2015
July 07, 2015 16:05 ET
|
Peregrine Pharmaceuticals Inc.
TUSTIN, Calif., July 07, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company focused on developing novel investigational products...
Peregrine Pharmaceuticals Granted Key European Patent for Its Lead Clinical Drug Candidate Bavituximab
June 25, 2015 08:30 ET
|
Peregrine Pharmaceuticals Inc.
-Bavituximab Patent Secured in Countries Across Europe- -Bavituximab Phase III Clinical Trial Underway at Over 150 Worldwide Clinical Sites Including Over 75 Sites in Eight European Countries- ...
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
June 05, 2015 08:30 ET
|
Peregrine Pharmaceuticals Inc.
TUSTIN, Calif., June 5, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP) today announced that its Board of Directors has declared a quarterly cash dividend payment...
Data Presentations at ASCO Demonstrate the Ability of Peregrine Pharmaceuticals' Bavituximab to Activate Tumor Targeting Immune Cells in PD-L1 Negative NSCLC Tumors
June 01, 2015 09:00 ET
|
Peregrine Pharmaceuticals Inc.
- New Data Show that Bavituximab Alone and in Combination with Docetaxel Elicits a Tumor-Specific Immune Response in PD-L1 Negative Tumors Extracted from NSCLC Patients -
- PS-Targeting Antibodies...
Peregrine Pharmaceuticals Provides Update on Planned Expansion of Bavituximab Clinical Program
June 01, 2015 08:30 ET
|
Peregrine Pharmaceuticals Inc.
- Phase II Trial to Evaluate Combination of Bavituximab and Opdivo® (Nivolumab) in Non-Small Cell Lung Cancer -
- Phase II/III Combination Trial to Advance Bavituximab with Chemotherapy...
Peregrine Pharmaceuticals Enters Into Research Collaboration to Investigate Novel PS-Targeting Immunotherapy Combinations
May 29, 2015 08:30 ET
|
Peregrine Pharmaceuticals Inc.
TUSTIN, Calif., May 29, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP), a biopharmaceutical company focused on advancing bavituximab, a novel immuno-oncology...
Peregrine Pharmaceuticals Announces Webcast of Immunotherapy Roundtable at ASCO Annual Meeting
May 27, 2015 16:00 ET
|
Peregrine Pharmaceuticals Inc.
TUSTIN, Calif., May 27, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals (Nasdaq:PPHM) (Nasdaq:PPHMP), a biopharmaceutical company focused on advancing bavituximab, a novel immuno-oncology (I-O)...
Peregrine Pharmaceuticals' Immuno-Oncology Agent Bavituximab to be Highlighted in Three Presentations at 2015 ASCO Annual Meeting
May 13, 2015 17:00 ET
|
Peregrine Pharmaceuticals Inc.
TUSTIN, Calif., May 13, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP), a biopharmaceutical company focused on advancing bavituximab, a novel immuno-oncology...
Preclinical Data Presented at AACR Demonstrate Synergistic Anti-Tumor Effects of Peregrine Pharmaceuticals' Phosphatidylserine (PS)-Targeting Antibodies With Immune Checkpoint Inhibitors in Models of Melanoma and Breast Cancer
April 21, 2015 08:00 ET
|
Peregrine Pharmaceuticals Inc.
- Combination Treatment Reduces Tumor Immune System Blockade and Enhances Tumor Specific Immune Responses -
- Studies Reveal Significant Increases in Tumor-Infiltrating CD8+ T Cells and...